MSP2133 Citations (2)

Originally described in: High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.
Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Keith Joung J Nature. 2016 Jan 6. doi: 10.1038/nature16526. PubMed Journal

---

Articles Citing MSP2133

Articles
High-fidelity CRISPR/Cas9- based gene-specific hydroxymethylation rescues gene expression and attenuates renal fibrosis. Xu X, Tan X, Tampe B, Wilhelmi T, Hulshoff MS, Saito S, Moser T, Kalluri R, Hasenfuss G, Zeisberg EM, Zeisberg M. Nat Commun. 2018 Aug 29;9(1):3509. doi: 10.1038/s41467-018-05766-5. PubMed
Treatment of Huntington's disease with a pan-HTT-targeting CRISPR nuclease. Tan K, Siller DDB, Xiong AY, Wang AXA, McCallister TX, Mummadi S, St John LA, Lee TK, Carrillo A, Renshaw DG, Zhou RH, Lim CKW, He J, Fields CJ, Hayden MR, Gaj T. bioRxiv [Preprint]. 2025 Dec 22:2025.12.20.695720. doi: 10.64898/2025.12.20.695720. PubMed

If you have published an article using this material, please email us at to have your article added to this page.